Silo Pharma Announces Strategic Business Expansion into Multi-Billion Dollar AI Agent Market with Acquisition of Managed AI Agent Platform, Qwikagents
Silo Pharma acquired the assets of Qwikagents.ai to launch a dedicated AI subsidiary, marking a strategic diversification beyond its biopharma roots into the autonomous agent market. The new business unit targets a sector projected to reach $47–$53 billion by 2030, with proprietary smart-routing technology aimed at optimizing cost and performance.
Key figures
- Drug Name
- SPC-15
- Phase Of Trial
- Phase 1
- Ai market growth rate
- 43% to 50%
- Ai market size projection 2030
- $47–$53 billion
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.